Cangrelor

Drug Profile

Cangrelor

Alternative Names: AR-C 69931; AR-C69931MX; Kengreal; Kengrexal

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Adenine nucleotides; Antiplatelets; Small molecules
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Coronary artery disease; Coronary thrombosis
  • No development reported Acute coronary syndromes

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute coronary syndromes in USA (IV)
  • 03 Jan 2017 Phase-I clinical trials in Coronary thrombosis (In neonates, Prevention) in USA (IV) (NCT02765633)
  • 15 Nov 2016 Launched for Coronary thrombosis (Prevention) and Coronary artery disease in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top